Find and Pitch Jounalists, Get Your Story Covered

Tags: leadership pharma Research & Development research-development biotech

	Profile	Recent Articles on Subject
1	Angus Chen STAT News Undignified, unfunny journalist. Health, cancer coverage at STAT News. journalismhealthcancer researchSTAT News	Biopharma leaders lay out vision for the future of blood cancer treatment - 12 days ago
2	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	Biopharma leaders lay out vision for the future of blood cancer treatment - 12 days ago A biotech’s binary bet ends badly - 6 months ago
3	Jonathan Wosen STAT News West Coast Biotech Reporter. Formerly @sdut. Stanford PhD. UCSC alum. San Diego, California BiotechLife SciencesImmunology	Biopharma leaders lay out vision for the future of blood cancer treatment - 12 days ago STAT+: Pharmalittle: End of biotech’s stock market malaise may be near; cancer drug shortages hit rural clinics hard - about 1 year ago
4	Meghana Keshavan STAT News Biotech nerd and writer @statnews. biotechwriting	Biopharma leaders lay out vision for the future of blood cancer treatment - 12 days ago Is pharma still fearful of the Inflation Reduction Act? - 4 months ago The biotech news you missed this week - 6 months ago STAT+: More tumult at BIO amid the company’s fourth CEO in four years - 7 months ago The legal pathway for experimental, ultra-rare disease treatments is rocky and expensive - about 1 year ago FDA chastens pet companies over antibiotics - about 1 year ago Novartis is building a new radioligand plant in China - about 1 year ago
5	Meagan Parrish Pharma Voice Senior editor @industrydive. Pharma world follower. Wisconsin, USA pharmaceuticalsjournalismparenting	The big rebrand: Why these 4 biopharmas changed their name this year - 16 days ago Pharma takes aim at a wily foe — the Epstein-Barr virus - about 2 months ago 2024 PharmaVoice 100s: Rare Disease Warriors - about 2 months ago 2024 PharmaVoice 100s: Trailblazers - 2 months ago California is a life sciences leader. Joe Panetta has been one of its most vocal advocates. - 3 months ago Who’s winning in biotech’s tight market? - 3 months ago Pharma’s ‘it’ therapy — a new drug class gaining steam - 4 months ago What pharma has learned from AI - 5 months ago Up-and-comers look for an edge in the bustling ADC field - 6 months ago Pharma’s R&D gamble: picking pipeline winners in a risky field - 7 months ago Where competition is heating up in pharma - 7 months ago The biggest questions hanging over pharma in 2024 - 11 months ago PharmaVoice’s Crystal Ball: What’s next in drug innovation and clinical trials - 11 months ago Does BioMarin’s CEO shuffle signal bigger changes ahead? - about 1 year ago PharmaVoice 100s: Entrepreneurs - about 1 year ago
6	Amy Baxter Pharma Voice Scientist, inventor, former pediatrician. Atlanta, Georgia pain relieftechnologyinnovation	Milk-based therapies could be coming. This biotech CEO is aiming to lead the way. - 18 days ago Can BioNTech sustain a post-COVID mRNA pipeline? Oncology is the next hope. - 4 months ago In a Duchenne market beset by problems, Capricor data marks a bright spot - 5 months ago Behind the powerful computations, AI’s role in pharma is still beset by challenges - 6 months ago 4 offbeat biotechs making a splash in the life sciences - 8 months ago These biotech hotspots are ripe for IPOs - 9 months ago
7	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Pharmalittle: We’re reading about GSK leaving BIO, an AbbVie schizophrenia drug failing, and more - about 1 month ago STAT+: Pharmalittle: We’re reading about biotech startups, Pfizer’s RSV vaccine, and more - 9 months ago STAT+: Pharmalittle: We’re reading about Biocon eyeing weight loss drugs, Sanofi layoffs, and more - 9 months ago STAT+: Pharmalittle: We’re reading about Boehringer biosimilar frustrations, FTC warnings, and more - 9 months ago STAT+: Pharmalittle: We’re reading about BIO cutting ties with WuXi, EU pharma rules, and more - 9 months ago STAT+: Pharmalittle: We’re reading about Lilly selling drugs directly, UCB leaving BIO, and more news - 12 months ago STAT+: Pharmalittle: FDA approvals rebound, abortion pill orders rise, and more news - 12 months ago STAT+: Pharmalittle: Bristol Myers to buy schizophrenia-drug maker; Servier found guilty of fraud - 12 months ago STAT+: Pharmalittle: Weight loss drugs are being paired with bariatric surgery; Carl Icahn plans to oust Illumina directors - about 1 year ago STAT+: Pharmalittle: Pfizer is leaving the BIO trade group; CVS drug-pricing plan may not lower costs for consumers - about 1 year ago STAT+: Pharmalittle: Bioscience job market is upside down; Sanofi and Regeneron’s blockbuster Dupixent may find bigger market - about 1 year ago STAT+: Pharmalittle: Pharma moves closer to a pricing deal with U.K.; FDA to review AstraZeneca request for self-administered flu vax - about 1 year ago STAT+: Pharmalittle: Life sciences deals on track to hit lowest point since 2017; EU regulators order Illumina to divest Grail - about 1 year ago
8	Sarah Owermohle STAT News Health reporter @STATNews. Covers Biden's agenda. Washington, District of Columbia health policyjournalism	STAT+: Pharma giant GSK is quitting BIO in latest setback for the lobbying group - about 1 month ago
9	John Wilkerson STAT News STAT Washington correspondent. Healthcare Journalism	STAT+: Pharma giant GSK is quitting BIO in latest setback for the lobbying group - about 1 month ago
10	Lizzy Lawrence STAT News Medical devices reporter at STATnews. Loves news tips. medical reportingnews	STAT+: Pharma giant GSK is quitting BIO in latest setback for the lobbying group - about 1 month ago

Journalists covering biopharma